Xie FF, Zhang YF, Hu YF, Xie YY, Wang XY, Wang SZ, Xie BQ. Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis. World J Clin Cases 2022; 10(5): 1527-1535 [PMID: 35211590 DOI: 10.12998/wjcc.v10.i5.1527]
Corresponding Author of This Article
Bao-Qiang Xie, BM BCh, Chief Doctor, Department of Endocrinology, Guangdong Provincial People's Hospital Ganzhou Hospital (Ganzhou Municipal Hospital), No. 49 Dagong Road, Zhanggong District, Ganzhou 341000, Jiangxi Province, China. xiebaoqiang1629@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Fei-Fei Xie, Yu-Fang Zhang, Yan-Fang Hu, Yun-Yun Xie, Xiao-Ying Wang, Shu-Zhen Wang, Bao-Qiang Xie, Department of Endocrinology, Guangdong Provincial People’s Hospital Ganzhou Hospital (Ganzhou Municipal Hospital), Ganzhou 341000, Jiangxi Province, China
Author contributions: Xie FF and Zhang YF designed the experiment; Hu YF drafted the work; Xie YY, Wang XY, and Wang SZ collected the data; Xie BQ and Xie FF analyzed and interpreted the data; and Zhang YF, Hu YF, and Xie YY wrote the article.
Supported byJiangxi Provincial Health and Family Planning Commission “Science and Technology Plan”.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Guangdong Provincial People’s Hospital Ganzhou Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: November 14, 2021 Peer-review started: November 14, 2021 First decision: December 9, 2021 Revised: December 27, 2021 Accepted: January 11, 2022 Article in press: January 11, 2022 Published online: February 16, 2022 Processing time: 88 Days and 21.4 Hours
ARTICLE HIGHLIGHTS
Research background
Osteoporosis is a systemic bone disease characterized by decreased bone mass, damaged bone mass, and decreased bone strength, leading to increased bone fragility and fractures. Type 2 diabetes (T2DM) complicated by osteoporosis is a common systemic metabolic bone disease. The reduction of bone mass and bone strength is considered to be the main clinical feature; its occurrence is considered to be related to gender, age and genetic factors.
Research motivation
Explore the risk factors of T2DM complicated with osteoporosis, and provide reasonable guidance for preventing this problem.
Research objectives
This study aimed to investigate the relationships among serum glucagon-like peptide-1 (GLP-1) levels, matrix Gla protein (MGP) levels, and diabetes with osteoporosis.
Research methods
Sixty T2DM patients with osteoporosis were selected as the case group, and 60 T2DM patients with bone loss were selected as the control group. Sixty healthy subjects were selected as the healthy group for the study.
Research results
Serum GLP-1 and MGP levels in diabetic osteoporosis patients are independent risk factors for osteoporosis in diabetic patients.
Research conclusions
Serum GLP-1 and MGP levels of diabetic patients with osteoporosis were significantly decreased and positively correlated with bone mineral density and were independent risk factors for osteoporosis in diabetic patients.
Research perspectives
Provide for the prevention of osteoporosis in diabetic patients.
